Foghorn Therapeutics Inc. Company Profile
NASDAQ: FHTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Foghorn Therapeutics at a glance
Foghorn Therapeutics Inc. (NASDAQ: FHTX) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Watertown, MA. Foghorn Therapeutics is led by Mr. Adrian H. B. Gottschalk and employs about 106 people. The company's shares have traded publicly since 2020.
At a market capitalization of $103.1 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001822462, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Foghorn Therapeutics do?
Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, ovarian, and bladder cancer; and diffuse large B-cell lymphoma, as well as various acute myeloid leukemia and myelodysplastic syndrome. The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Foghorn Therapeutics Inc.
- Ticker
- NASDAQ: FHTX
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Adrian H. B. Gottschalk
- Employees
- 106
- Headquarters
- 99 Coolidge Avenue, Watertown, MA, United States
- Phone
- 617 586 3100
- Website
- foghorntx.com
- IPO year
- 2020
- Market cap
- $103.14M
- SEC CIK
- 0001822462
- Latest annual report
- 10-K · Mar 11, 2026
Companies similar to Foghorn Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| GNLXGenelux Corporation | 2.17 | -4.82% | $103.36M | vs FHTX |
| ORGOOrganogenesis Holdings Inc. Class A | 0.7716 | -2.23% | $100.16M | vs FHTX |
| NERVMinerva Neurosciences Inc | 2.00 | -5.66% | $99.67M | vs FHTX |
| AKBAAkebia Therapeutics Inc. | 0.3855 | -8.71% | $107.04M | vs FHTX |
| CNTNCanton Strategic Holdings Inc. | 1.21 | -1.63% | $98.78M | vs FHTX |
| UNCYUnicycive Therapeutics Inc. | 3.35 | -5.10% | $97.77M | vs FHTX |
| BGMBGM Group Ltd. Class A | 8.13 | 0.00% | $108.57M | vs FHTX |
| SPRBSpruce Biosciences Inc. | 38.00 | -6.15% | $109.21M | vs FHTX |